Nothing Special   »   [go: up one dir, main page]

BR0004530A - Process for manufacturing topical ophthalmic preparations without systemic effects - Google Patents

Process for manufacturing topical ophthalmic preparations without systemic effects

Info

Publication number
BR0004530A
BR0004530A BR0004530-6A BR0004530A BR0004530A BR 0004530 A BR0004530 A BR 0004530A BR 0004530 A BR0004530 A BR 0004530A BR 0004530 A BR0004530 A BR 0004530A
Authority
BR
Brazil
Prior art keywords
topical
preparations
systemic
effects
systemic effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0004530-6A
Other languages
Portuguese (pt)
Inventor
Bakulesh Mafatlal Khamar
Original Assignee
Bakulesh Mafatlal Khamar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bakulesh Mafatlal Khamar filed Critical Bakulesh Mafatlal Khamar
Publication of BR0004530A publication Critical patent/BR0004530A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção para: <B>"PROCESSO PARA MANUFATURAMENTO DE PREPARAçõES OFTáLMICAS TóPICAS SEM EFEITOS SISTêMICOS"<D>. Para tratamento de doenças do olho, vários tipos de medicações são usadas. Elas são usadas na forma de preparações tópicas ou na forma de preparações sistêmicas para serem tomadas oralmente ou parenteralmente. De preparações tópicas, algumas são para uso tópico somente, por exemplo., framicetina, neomicina, loteprednol ebanoato, etc. Contudo, a grande maioria de drogas oftálmicas tópicas são para uso sistêmico também, por exemplo, Ciprofloxacina, Gentamicina, Timolol, Clonidina, Dexametasona, Betametasona, Carbachol, etc. Algumas destas drogas quando usadas topicamente são também verificadas apresentarem efeitos sistêmicos e se elas são de natureza séria, limitam o uso desta droga, por exemplo., efeitos cardio-pulmonares de ß-bloqueadores similares a timolol. Secura da boca, rubor, febre, taquicardia, retenção urinária, convulsão, irritabilidade com atropina. Hiper-tensão com fenilefina. Salivamento aumentado, náusea, vómito, diarréia, cólicas estomacais, secreções bronquiais, constrição bronquial, asma, bradicardia, parestesia com mióticos, Hipotensão com clonidina. Boca seca, fadiga e sonolência com apraclonidina e brimonidina.Invention Patent for: <B> "PROCESS FOR MANUFACTURING TOPICAL OPHTHALIC PREPARATIONS WITHOUT SYSTEMIC EFFECTS" <D>. For treating eye diseases, several types of medications are used. They are used in the form of topical preparations or in the form of systemic preparations to be taken orally or parenterally. Of topical preparations, some are for topical use only, for example, framicetin, neomycin, loteprednol ebanoate, etc. However, the vast majority of topical ophthalmic drugs are also for systemic use, for example, Ciprofloxacin, Gentamicin, Timolol, Clonidine, Dexamethasone, Betamethasone, Carbachol, etc. Some of these drugs when used topically are also found to have systemic effects and if they are of a serious nature, they limit the use of this drug, for example, cardio-pulmonary effects of ß-blockers similar to timolol. Dry mouth, flushing, fever, tachycardia, urinary retention, seizure, irritability with atropine. Hypertension with phenylephrine. Increased salivation, nausea, vomiting, diarrhea, stomach cramps, bronchial secretions, bronchial constriction, asthma, bradycardia, paresthesia with miotics, Hypotension with clonidine. Dry mouth, fatigue and drowsiness with apraclonidine and brimonidine.

BR0004530-6A 1999-02-03 2000-02-02 Process for manufacturing topical ophthalmic preparations without systemic effects Pending BR0004530A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN90BO1999 IN185228B (en) 1999-02-03 1999-02-03
PCT/IN2000/000008 WO2000049990A2 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects

Publications (1)

Publication Number Publication Date
BR0004530A true BR0004530A (en) 2001-04-03

Family

ID=11077485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004530-6A Pending BR0004530A (en) 1999-02-03 2000-02-02 Process for manufacturing topical ophthalmic preparations without systemic effects

Country Status (11)

Country Link
EP (1) EP1139970A2 (en)
AP (1) AP2000001977A0 (en)
AU (1) AU4429100A (en)
BR (1) BR0004530A (en)
CA (1) CA2326690A1 (en)
EA (1) EA200000918A1 (en)
ID (1) ID28121A (en)
IL (1) IL138824A0 (en)
IN (1) IN185228B (en)
WO (1) WO2000049990A2 (en)
ZA (1) ZA200006252B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005220199B2 (en) * 2000-07-14 2007-03-08 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU7326901A (en) * 2000-07-14 2002-01-30 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
DE10132876A1 (en) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Two-phase, drop-onable hydrogels for use on the eye
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
PT1761266E (en) 2004-05-25 2013-06-04 Galderma Pharma Sa Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
FR2977493B1 (en) 2011-07-05 2014-02-14 Galderma Res & Dev NOVEL STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS
AU2014216112B2 (en) 2013-02-15 2019-02-21 Allergan, Inc. Sustained drug delivery implant
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
GB202110420D0 (en) * 2021-07-20 2021-09-01 Rosemont Pharmaceuticals Ltd Liquid pharmaceutical composition of clonidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (en) * 1977-11-07 1985-12-11 東興薬品工業株式会社 eye drops
DD294174A5 (en) * 1990-05-04 1991-09-26 Sigrid Keipert OPHTHALMIKA WITH RESET EFFECT AND A NEW PROCESS FOR THEIR MANUFACTURE
FR2678832B1 (en) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire NOVEL OPHTHALMIC COMPOSITIONS WITH IMPROVED RESORPTION AND METHODS OF PREPARING THE SAME.
FR2679773A1 (en) * 1991-07-30 1993-02-05 Merck Sharp & Dohme Ophthalmic preparation containing an acceptable antimicrobial osmotic agent
DE19614823A1 (en) * 1996-04-15 1997-10-16 Mann Gerhard Chem Pharm Fab Ophthalmic composition with prolonged retention time on the eye

Also Published As

Publication number Publication date
EP1139970A2 (en) 2001-10-10
IL138824A0 (en) 2001-10-31
ID28121A (en) 2001-05-03
WO2000049990A2 (en) 2000-08-31
WO2000049990A3 (en) 2001-07-26
AU4429100A (en) 2000-09-14
ZA200006252B (en) 2001-11-29
IN185228B (en) 2000-12-09
AP2000001977A0 (en) 2000-12-31
EA200000918A1 (en) 2001-10-22
CA2326690A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
BR0004530A (en) Process for manufacturing topical ophthalmic preparations without systemic effects
CA2460140A1 (en) Compositions for treatment of common cold
BR0307893A (en) Ophthalmic formulation with gum system
BR9812361A (en) Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis / conjunctivitis and symptoms of virus infection, similar to virus infection and / or cold
BR0109779A (en) Carvedilol hydrophilic dispersed molecular solutions
ITMI20022323A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC DISEASES.
AR048878A1 (en) TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE
BRPI0707043C1 (en) Oxycodone-based water-insoluble matrix tablets, their manufacturing process and use of a pharmaceutical composition
WO2004071469A3 (en) Methods of administering a dermatological agent to a subject
EA200800337A1 (en) COMPOSITION AND METHOD OF INTRODUCTION OF OPHTHALMOLOGICALLY ACTIVE MEANS
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
BR9913060A (en) Positive electrode material and process for its manufacture
BR0214430A (en) Amino Acid and Riboflavin Formulation Useful to Reduce Toxic Effects of Cytotoxic Chemotherapy
BR0305628A (en) Pharmaceutical composition for treating sexual dysfunction in a mammal comprising peptide and its use
BR9814721A (en) &#34;use of polyols, appropriate device for the treatment or prophylaxis of mucosal infection caused by yeast in mammals, process for therapeutic or prophylactic treatment of mammals suffering from or being subjected to an increased risk of infection of the mucosa caused by yeast, composition for use in this treatment, and, pharmaceutical preparation for use in the prophylactic or therapeutic systemic or topical treatment of mucosal infections caused by yeast. &#34;
BR0313213A (en) highly dispersible precipitating silicic acid with larger surface
BR0116749A (en) uses of artemine or its agonist and articles of manufacture
CO5580787A2 (en) NEW METHODS FOR THE TREATMENT OF LOCAL BACTERIAL AND MICOTIC INFECTIONS
BRPI0513673A (en) method for increasing the efficacy and transport of enterally administered biologically active compounds, a vehicle used for enteral administration of biologically active compounds, a pharmaceutical composition and the use of an effective amount of one or more phosphate derivatives
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
AR069831A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLADDER CANCER
WO2005028616A3 (en) Morphogen compositions and methods of use thereof to treat heart disorders
Schep et al. Primary interactions of three quaternary ammonium compounds with blastospores of Candida albicans (MEN strain)
PE20000861A1 (en) ORAL LIQUID MUCOADHESIVE COMPOSITIONS
BR0214487A (en) A pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for the treatment of diabetes.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]